Taylors Lakes’ Sienna Gec followed in her sister’s footsteps as she claimed the Little Athletics Victorian Handicap 100 metre girls ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Amid everything from the COVID-19 pandemic to recent upswells of influenza and RSV, vaccines have become as common a ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Armed with lab equipment and two months of food and clothes, around 60 researchers boarded the RSV Nuyina icebreaker ship for ...

Dianne Elliot took a three-week, seven-country trip that included stops in the United Kingdom, Egypt, India, Cambodia, Jordan, Indonesia and Oman. Some of those countries require ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Meeting, held April 24–28 in Honolulu, reveals that young children with chronic conditions are more likely to be hospitalized ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.